TY - JOUR
T1 - Progress towards elimination of viral hepatitis
T2 - a Lancet Gastroenterology & Hepatology Commission update
AU - Cooke, Graham S.
AU - Flower, Barnaby
AU - Cunningham, Evan
AU - Marshall, Alison D.
AU - Lazarus, Jeffrey V.
AU - Palayew, Adam
AU - Jia, Jidong
AU - Aggarwal, Rakesh
AU - Al-Mahtab, Mamum
AU - Tanaka, Yashuito
AU - Jeong, Sook Hyang
AU - Poovorawan, Kittiyod
AU - Waked, Imam
AU - Hiebert, Lindsey
AU - Khue, Pham M.
AU - Grebely, Jason
AU - Alcantara-Payawal, Diana
AU - Sanchez-Avila, Juan F.
AU - Mbendi, Charles
AU - Muljono, David H.
AU - Lesi, Olufunmilayo
AU - Desalegn, Hailemichael
AU - Hamid, Saeed
AU - de Araujo, Alexandre
AU - Cheinquer, Hugo
AU - Onyekwere, Charles A.
AU - Malyuta, Ruslan
AU - Ivanchuk, Iryna
AU - Thomas, David L.
AU - Pimenov, Nikolay
AU - Chulanov, Vladimir
AU - Dirac, Mae Ashworth
AU - Han, Hannah
AU - Ward, John W.
N1 - Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2024/4
Y1 - 2024/4
N2 - The top 20 highest burdened countries (in disability-adjusted life years) account for more than 75% of the global burden of viral hepatitis. An effective response in these 20 countries is crucial if global elimination targets are to be achieved. In this update of the Lancet Gastroenterology & Hepatology Commission on accelerating the elimination of viral hepatitis, we convene national experts from each of the top 20 highest burdened countries to provide an update on progress. Although the global burden of diseases is falling, progress towards elimination varies greatly by country. By use of a hepatitis elimination policy index conceived as part of the 2019 Commission, we measure countries' progress towards elimination. Progress in elimination policy has been made in 14 of 20 countries with the highest burden since 2018, with the most substantial gains observed in Bangladesh, India, Indonesia, Japan, and Russia. Most improvements are attributable to the publication of formalised national action plans for the elimination of viral hepatitis, provision of publicly funded screening programmes, and government subsidisation of antiviral treatments. Key themes that emerged from discussion between national commissioners from the highest burdened countries build on the original recommendations to accelerate the global elimination of viral hepatitis. These themes include the need for simplified models of care, improved access to appropriate diagnostics, financing initiatives, and rapid implementation of lessons from the COVID-19 pandemic.
AB - The top 20 highest burdened countries (in disability-adjusted life years) account for more than 75% of the global burden of viral hepatitis. An effective response in these 20 countries is crucial if global elimination targets are to be achieved. In this update of the Lancet Gastroenterology & Hepatology Commission on accelerating the elimination of viral hepatitis, we convene national experts from each of the top 20 highest burdened countries to provide an update on progress. Although the global burden of diseases is falling, progress towards elimination varies greatly by country. By use of a hepatitis elimination policy index conceived as part of the 2019 Commission, we measure countries' progress towards elimination. Progress in elimination policy has been made in 14 of 20 countries with the highest burden since 2018, with the most substantial gains observed in Bangladesh, India, Indonesia, Japan, and Russia. Most improvements are attributable to the publication of formalised national action plans for the elimination of viral hepatitis, provision of publicly funded screening programmes, and government subsidisation of antiviral treatments. Key themes that emerged from discussion between national commissioners from the highest burdened countries build on the original recommendations to accelerate the global elimination of viral hepatitis. These themes include the need for simplified models of care, improved access to appropriate diagnostics, financing initiatives, and rapid implementation of lessons from the COVID-19 pandemic.
UR - http://www.scopus.com/inward/record.url?scp=85186500271&partnerID=8YFLogxK
U2 - 10.1016/S2468-1253(23)00321-7
DO - 10.1016/S2468-1253(23)00321-7
M3 - Review article
C2 - 38367629
AN - SCOPUS:85186500271
SN - 2468-1253
VL - 9
SP - 346
EP - 365
JO - The Lancet Gastroenterology and Hepatology
JF - The Lancet Gastroenterology and Hepatology
IS - 4
ER -